121 related articles for article (PubMed ID: 35239349)
1. Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma.
Chen X; Liu L; Liu P; Chen Y; Lin D; Yan H; Yan Q; Wang Y; Qiu Y; Fang B; Huang H; Qian J; Zhao Y; Du Z; Zhang Q; Li X; Zheng X; Liu Z
J Med Chem; 2022 Apr; 65(7):5374-5391. PubMed ID: 35239349
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent thiazolidin-4-one sulfone derivatives for inhibition of proliferation of osteosarcoma in vitro and in vivo.
Chen X; Luo Z; Hu Z; Sun D; He Y; Lu J; Chen L; Liu S
Eur J Med Chem; 2024 Feb; 266():116082. PubMed ID: 38232462
[TBL] [Abstract][Full Text] [Related]
4. PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology.
Maniscalco L; Iussich S; Morello E; Martano M; Biolatti B; Riondato F; Della Salda L; Romanucci M; Malatesta D; Bongiovanni L; Tirrito F; Gattino F; Buracco P; De Maria R
Vet J; 2013 Jan; 195(1):41-7. PubMed ID: 22704137
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Pharmacological Evaluation of σ2 Receptor Ligands Based on a 3-Alkoxyisoxazole Scaffold: Potential Antitumor Effects against Osteosarcoma.
Shi JJ; Jia KH; Sun H; Gunosewoyo H; Yang F; Tang J; Luo J; Yu LF
ChemMedChem; 2021 Feb; 16(3):524-536. PubMed ID: 32964625
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.
Zaman GJ; Vink PM; van den Doelen AA; Veeneman GH; Theunissen HJ
Biochem Pharmacol; 1999 Jan; 57(1):57-64. PubMed ID: 9920285
[TBL] [Abstract][Full Text] [Related]
10. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
11. GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo.
Zhang Z; Ren X; Lu X; Wang D; Hu X; Zheng Y; Song L; Pang H; Yu R; Ding K
Cancer Lett; 2016 May; 375(1):172-178. PubMed ID: 26940138
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines.
Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM
Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.
Kadivar A; Kamalidehghan B; Akbari Javar H; Karimi B; Sedghi R; Noordin MI
Drug Des Devel Ther; 2017; 11():469-481. PubMed ID: 28260860
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
16. Potent platelet-derived growth factor-beta receptor (PDGF-betaR) inhibitors: Synthesis and structure-activity relationships of 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one derivatives.
Aoki K; Obata T; Yamazaki Y; Mori Y; Hirokawa H; Koseki J; Hattori T; Niitsu K; Takeda S; Aburada M; Miyamoto K
Chem Pharm Bull (Tokyo); 2007 Feb; 55(2):255-67. PubMed ID: 17268099
[TBL] [Abstract][Full Text] [Related]
17. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin.
Daoussis D; Tsamandas AC; Liossis SN; Antonopoulos I; Karatza E; Yiannopoulos G; Andonopoulos AP
Arthritis Res Ther; 2012 Jun; 14(3):R145. PubMed ID: 22697462
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic derivatives of platelet-derived growth factor receptors.
Jones AV; Cross NC
Cell Mol Life Sci; 2004 Dec; 61(23):2912-23. PubMed ID: 15583853
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-β axis.
Zhang D; Cui G; Sun C; Lei L; Lei L; Williamson RA; Wang Y; Zhang J; Chen P; Wang A; Fan R; Han S; Wang Y; Hu J
Biochem Biophys Res Commun; 2019 Apr; 512(2):360-366. PubMed ID: 30894277
[TBL] [Abstract][Full Text] [Related]
20. Marine derived hamacanthins as lead for the development of novel PDGFRβ protein kinase inhibitors.
Pinchuk B; Johannes E; Gul S; Schlosser J; Schaechtele C; Totzke F; Peifer C
Mar Drugs; 2013 Aug; 11(9):3209-23. PubMed ID: 24065162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
